Naldemedine works by selectively antagonizing opioid receptors in the gastrointestinal tract without impacting the central nervous system’s analgesic pathways. This unique mechanism allows patients to continue benefiting from opioid analgesia while preserving natural bowel function. Prior clinical investigations have established that starting naldemedine alongside opioid therapy not only prevents constipation but also alleviates related symptoms such as nausea, substantially improving patients’ well-being.

Despite this clinical promise, Japan’s public health insurance system has yet to approve reimbursement for the prophylactic use of naldemedine—a status that restricts its adoption as a standard preventive measure. Addressing this obstacle, the recent economic evaluation meticulously compared costs against health outcomes in patients newly prescribed strong opioids for cancer pain.

The study’s cost-effectiveness analysis revealed an incremental cost-effectiveness ratio (ICER) of approximately 1.45 million Japanese yen per quality-adjusted life year (QALY) gained. This figure comfortably falls below Japan’s established willingness-to-pay threshold of 5 million yen per QALY, underscoring the intervention’s favorable economic profile within Japan’s healthcare framework.

Beyond monetary considerations, these findings hold substantial clinical implications. By preventing OIC, prophylactic naldemedine can enhance symptom control, reduce gastrointestinal side effects, and support patients’ adherence to opioid regimens. Sustained opioid compliance is crucial for maintaining effective analgesia in palliative care, where uncontrolled pain significantly impairs patient quality of life.

The researchers emphasize that incorporating prophylactic naldemedine into cancer pain management protocols could reshape palliative care standards, promoting both improved symptom relief and cost-effective resource utilization. These data equip policymakers and clinicians with compelling evidence to advocate for expanded insurance coverage and guideline inclusion.

Published in the Journal of Palliative Medicine, the study marks a pivotal advance toward integrating pharmacoeconomic insights into pain management strategies. As the global burden of cancer pain grows, adopting such interventions that balance efficacy with affordability will be essential for optimizing patient outcomes.

Future investigations may focus on broader population analyses and real-world implementation studies to validate these findings further and address any remaining barriers to access. Meanwhile, the current evidence firmly positions prophylactic naldemedine as a transformative option in mitigating one of opioid therapy’s most challenging side effects.

Subject of Research: Opioid-induced constipation prevention in cancer patients
Article Title: Cost-Effectiveness of Prophylactic Naldemedine for Opioid-Induced Constipation in Patients with Cancer
News Publication Date: April 10, 2026
Web References: https://doi.org/10.1177/10966218261440391
References: Journal of Palliative Medicine
Keywords: opioid-induced constipation, naldemedine, cancer pain, cost-effectiveness, quality-adjusted life years, palliative care

Radiation therapy remains a cornerstone of cancer treatment, contributing to approximately 40% of cancer cures globally. The advancements showcased at the 2026 meeting will underscore this essential role, focusing on cutting-edge technologies and innovative treatment paradigms. ASTRO’s commitment to integrating data-driven insights with clinical application is designed to foster a holistic understanding of radiotherapy’s impact. It emphasizes the importance of translating complex research findings into meaningful patient conversations and shaping public and professional perceptions of this vital therapeutic approach.

One of the highlights of the upcoming Annual Meeting includes an extensive array of over 2,500 research presentations and posters. These works will feature novel findings in radiation medicine and oncology, spotlighting breakthroughs in cancer biology, radiation delivery techniques, and the integration of multimodal therapies. Attendees will have the opportunity to engage with pioneering research spanning from basic science to clinical trials, thereby broadening their expertise and enabling the incorporation of novel knowledge into everyday clinical practice.

The conference’s keynote lineup brings together prominent figures in the medical and regulatory communities. Dr. Scott Gottlieb, former Commissioner of the U.S. Food and Drug Administration (FDA), will offer insights into regulatory science, innovation, and the evolving landscape of cancer therapeutics. Alongside him, Dr. Ezekiel Emanuel, a distinguished oncologist and bioethicist, will explore the ethical dimensions and policy implications surrounding radiation oncology. Their addresses will provide attendees with a comprehensive understanding of both the scientific advancements and the societal contexts within which radiotherapy operates.

ASTRO’s Presidential Symposium, a focal event within the conference, will delve deeply into the multifaceted benefits of radiotherapy. Sessions will address themes such as organ preservation—a critical consideration in maintaining patient quality of life—and will feature panels that incorporate patient perspectives alongside expert opinions. This symposium is designed to highlight the patient-centered nature of radiation oncology, emphasizing collaborative strategies and personalized care approaches that optimize therapeutic outcomes.

In addition to scientific dissemination, the Annual Meeting will feature specialized panel discussions and workshops addressing pressing challenges and future directions in cancer care. Topics include the growing influence of artificial intelligence in treatment planning and outcome prediction, the expanding field of radiopharmaceutical therapy, and strategies for disaster preparedness that ensure continuity of cancer care under adverse conditions. A unique storytelling workshop will also present the development of radiation oncology centers in low-to-middle-income countries, underscoring global health equity and capacity-building efforts.

The ASTRO Gold Medal Gala promises to be a prestigious occasion, honoring individuals who have made extraordinary contributions to the field of radiation oncology. Proceeds from this event will support Speed of Light – The ASTRO Foundation, which is dedicated to advancing research and innovation within the specialty. This gala highlights ASTRO’s commitment not only to scientific excellence but also to fostering community and philanthropy within the oncology discipline.

For members of the press, ASTRO will organize news briefings featuring high-impact research presented at the meeting. These briefings provide a platform to disseminate groundbreaking findings to a broader audience, amplifying the reach and influence of novel scientific developments. The embargo policy, which restricts the release of abstracts until late afternoon on September 25, 2026, ensures coordinated and responsible communication of emerging data.

In response to evolving attendees’ needs, the 2026 Annual Meeting will support both in-person participation in Boston and virtual attendance through livestreams of all scientific and educational sessions. This hybrid model facilitates broader access and engagement, allowing global participants to benefit from the latest developments regardless of geographic or logistical constraints. The on-site exhibit hall will showcase innovative patient care technologies, offering attendees hands-on experiences with the tools shaping the future of radiation oncology.

ASTRO also commits to supporting media professionals through a dedicated press office located within the Menino Convention Center, equipped to facilitate interviews and provide logistical assistance. This infrastructure underscores the society’s emphasis on clear and effective communication with the global media, further promoting wider dissemination of critical information in radiation therapy and cancer care.

Founded as the largest professional society in radiation oncology worldwide, ASTRO represents a multidisciplinary membership exceeding 10,000 clinicians, physicists, dosimetrists, and other healthcare professionals. The society’s mission remains focused on improving patient outcomes through clinical care, expanding research horizons, providing robust education, and advocating for informed health policies. The upcoming Annual Meeting in Boston epitomizes ASTRO’s strategic vision to integrate scientific rigor with translational impact, fostering advancements that resonate across both medical communities and patient populations.

For more detailed information, including registration procedures and eligibility criteria, interested parties are encouraged to visit ASTRO’s official website. Media registration details are accessible through the society’s dedicated press portal, ensuring that journalists and communications professionals have the necessary resources to cover this landmark event comprehensively. Through these efforts, ASTRO continues to champion the role of radiation therapy as an indispensable component of comprehensive cancer treatment globally.

Subject of Research: Radiation oncology, cancer treatment advances, and the communication of radiotherapy’s value in clinical care.

Article Title: ASTRO 2026 Annual Meeting: Advancing Radiation Oncology Through Data, Dialogue, and Innovation

News Publication Date: May 14, 2026

Web References:
– http://www.astro.org/annualmeeting
– http://www.astro.org/annualmeetingpress
– https://www.astro.org/meetings-and-education/micro-sites/2026/annual-meeting/learn/education-program/keynote-speakers
– https://www.astro.org/meetings-and-education/micro-sites/2026/annual-meeting/learn/education-program/presidential-symposium

Image Credits: American Society for Radiation Oncology (ASTRO)

Keywords: Radiation therapy, cancer treatment, oncology, clinical research, cancer cures, radiopharmaceutical therapy, artificial intelligence in oncology, patient-centered care, global health equity, medical innovation, data communication, cancer research

Glutamine functions as a critical nutrient that fuels tumor cells by providing both carbon and nitrogen essential for anabolic processes, energy production, and maintaining redox balance. Tumor cells exhibit an increased reliance on glutamine compared to normal cells, a phenomenon termed “glutamine addiction.” This metabolic reprogramming allows cancer cells to thrive in the nutrient-scarce and immunosuppressive tumor microenvironment. Understanding the molecular underpinnings of glutamine uptake and catabolism holds the key to effectively disrupting these metabolic dependencies and curbing tumor growth.

Central to glutamine’s role in cancer metabolism are specialized glutamine transporters embedded in the cellular membrane, which facilitate its uptake into tumor cells. Among these, the solute carrier family, including transporters such as SLC1A5, SLC7A5, and SLC38A2, has been shown to be upregulated in diverse malignancies. Therapeutic agents that inhibit these transporters aim to starve tumor cells by blocking glutamine influx, thereby depriving them of this vital resource. Such inhibitors represent a frontline strategy in metabolic cancer therapy due to their potential to selectively target tumor cells while sparing normal tissues.

One of the pioneering compounds in this class is V9302, a competitive antagonist that selectively binds to the glutamine transporter SLC1A5. Preclinical models in breast cancer have demonstrated that V9302 hampers glutamine transport, thereby promoting oxidative stress within tumor cells and triggering autophagy. These effects sensitize tumors to conventional chemotherapy and immune checkpoint inhibitors like anti-PD-1 antibodies, highlighting the promise of combination regimens. Innovative delivery systems incorporating V9302, such as reactive oxygen species (ROS)-responsive nanoparticles, have further enhanced targeted drug release and anti-tumor efficacy in preclinical uveal melanoma models.

Targeting another seminal transporter, SLC7A5, has also shown clinical promise. The inhibitor JPH203 binds with high affinity to SLC7A5, disrupting glutamine availability in tumor cells. Notably, JPH203’s efficacy has been validated in triple-negative breast cancer models where it not only alone curbs tumor progression but also acts synergistically with anti-PD-1 immunotherapy. This combinatorial effect potentiates immune activation and tumor regression, suggesting that metabolic blockade coupled with immune modulation could represent a transformative approach in resistant cancers.

Beyond the blockade of glutamine transport, a surge of interest centers on inhibiting glutaminase, the pivotal enzyme that converts glutamine to glutamate, facilitating glutamine catabolism and fueling the tricarboxylic acid (TCA) cycle. Targeting this enzymatic step directly disrupts cancer cell bioenergetics and biosynthesis. CB-839, a highly selective glutaminase inhibitor, has emerged as a frontrunner in this arena, demonstrating potent anti-proliferative effects in glutamine-dependent malignancies such as esophageal squamous cell carcinoma and lung cancer. By reducing glutaminase activity, CB-839 effectively limits the energy supply and biosynthetic precursors essential for tumor survival.

Advancements in nanotechnology have enabled the co-delivery of glutaminase inhibitors like CB-839 alongside photosensitizers to enhance photodynamic therapy (PDT) outcomes in gastric cancer. This multifunctional therapeutic strategy leverages the synergistic potential of metabolic inhibition and photoactivated cytotoxicity, resulting in greater tumor suppression. Moreover, novel glutaminase inhibitors such as IPN60090, when combined with CB-839, show promise in treating hematologic malignancies including myelodysplastic syndromes and acute myeloid leukemia by impairing NADPH-dependent cellular processes crucial for cancer cell proliferation.

Another remarkable compound in glutamine-targeted therapy is 6-diazo-5-oxo-L-norleucine (DON), a glutamine antagonist that irreversibly inhibits multiple enzymes involved in glutamine metabolism via covalent binding. Its efficacy in pancreatic ductal adenocarcinoma (PDAC) mouse models is particularly notable, where DON and its prodrug DRP-104 effectively suppress tumor proliferation and metastasis. The prodrug JHU-083, based on DON, offers an improved therapeutic index by selectively reducing tumor burden in lung cancer models without eliciting significant systemic toxicity, addressing a critical concern in metabolic cancer therapies.

The oncogene c-Myc, frequently dysregulated in cancer, upregulates glutaminase GLS1 expression and amplifies glutamine metabolism. The development of MYCi975, a novel MYC inhibitor, reveals a strategic front to disrupt this pathway. Treatment with MYCi975 in head and neck squamous cell carcinoma models significantly diminishes tumor cell proliferation and glutamine consumption. Moreover, dual inhibition combining MYCi975 and CB-839 synergizes to more effectively suppress tumor growth and metastasis than either agent alone, opening avenues for precision metabolic oncology.

KRAS-mutant tumors, notorious for their aggressive behavior, show upregulated expression of glutamine transporters and enzymes like GOT1 and GOT2 involved in the TCA cycle. Inhibiting transporters such as SLC7A5, SLC38A2, and mitochondrial glutamate carrier SLC25A22 presents strategic targets to thwart glutamine uptake and metabolism in these refractory cancers. Targeting this metabolic vulnerability holds immense therapeutic potential, especially in notoriously treatment-resistant KRAS-driven malignancies.

Beyond direct metabolic inhibition, metabolic-immunomodulatory strategies like the PD-L1-targeted metabolism and immunomodulator (PMIR) represent an innovative synthesis of immunotherapy and metabolism. PMIR curtails glutamine metabolism in tumors, thereby elevating glutamine availability within the TME, which enhances immune cell function. Simultaneously, PMIR suppresses PD-L1 expression on tumor cells, reversing immune evasion. This dual approach triggers immunogenic cell death, remodels the immunosuppressive TME, and robustly inhibits tumor progression and metastasis, underscoring the potential to combine metabolic reprogramming with immunotherapeutic interventions.

The clinical development of glutamine metabolism-targeted agents showcases significant progress toward realizing the therapeutic potential of metabolic vulnerabilities in cancer. These inhibitors of glutamine transport and catabolism have demonstrated encouraging efficacy and manageable safety profiles in diverse preclinical and early clinical settings. Nevertheless, the complexity of tumor metabolic networks and heterogeneity of glutamine dependency necessitate continued research to optimize treatment regimens, overcome resistance mechanisms, and identify patient populations most likely to benefit.

Intriguingly, combination therapies integrating glutamine inhibitors with other modalities such as chemotherapy, immunotherapy, and photodynamic therapy have exhibited enhanced antitumor responses. These multidimensional approaches leverage synthetic lethality and immune activation, indicating that targeting glutamine metabolism could serve as a critical axis in precision oncology. Personalized metabolic interventions, guided by biomarkers of glutamine dependence and metabolic flux analysis, represent the future frontier in cancer treatment.

Despite the remarkable advances, challenges persist in translating glutamine-targeted therapies from bench to bedside. Tumor metabolic plasticity, compensatory pathways, and potential off-target effects require sophisticated therapeutic designs and comprehensive mechanistic studies. The integration of systems biology, metabolomics, and advanced drug delivery systems will be crucial in tailoring glutamine metabolism inhibitors to clinical scenarios, maximizing efficacy while minimizing toxicity.

The burgeoning field of glutamine metabolism in the tumor microenvironment is rapidly redefining the landscape of cancer therapy. Harnessing glutamine’s central role offers a promising strategy to selectively impair tumor growth, overcome immune resistance, and enhance the benefits of existing treatment modalities. As research progresses, the intricate metabolic dance between cancer cells and their microenvironment reveals vulnerabilities ripe for exploitation, heralding a new era of cunning metabolic therapies poised to transform cancer care.

Subject of Research:
Glutamine metabolism as a therapeutic target in the tumor microenvironment for cancer treatment.

Article Title:
Glutamine: a new strategy for targeted metabolic therapy in the tumor microenvironment.

Article References:
Lv, H., Han, X., Yang, Y. et al. Glutamine: a new strategy for targeted metabolic therapy in the tumor microenvironment.
Cell Death Discov. 11, 459 (2025). https://doi.org/10.1038/s41420-025-02767-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02767-4

Cancer survivorship care encompasses a multifaceted approach that extends beyond the management of residual physical side effects from treatments such as chemotherapy, radiation, or surgery. It involves continuous surveillance for recurrence, screening for secondary malignancies, management of long-term treatment toxicities, and integration of mental health support. Given the varied nature of these needs, the delivery of surveillance and supportive care is inherently complex and demands coordinated efforts among multiple healthcare providers.

In recent exploratory research conducted by the University of Missouri School of Medicine, investigators delved into the experiences of female cancer survivors transitioning from acute oncology care to longer-term survivorship management overseen largely by primary care clinicians (PCCs). This stratified care shift aims to leverage the longitudinal and holistic relationship that primary care providers have with patients, but the study illuminated significant systemic and practical challenges impeding continuity of care. Among the 57 women surveyed and interviewed, only about one-third reported consistent contact with the same primary care clinician post-treatment, highlighting fragmentation risks.

The fragmented nature of survivorship care stems in part from unclear delineations of roles and responsibilities between oncologists and primary care practitioners. When transitioning patients after active treatment, ambiguity regarding who is accountable for surveillance protocols, symptom management, and psychological support can cause gaps in care continuity. Miscommunications between specialties and lapses in patient-provider relationships may exacerbate these discontinuities, potentially compromising early detection of recurrence or management of late effects.

Moreover, the research resonates with findings from previous studies that many primary care providers experience a lack of confidence and preparedness to deliver comprehensive survivorship care. Despite their willingness to engage in additional training, PCCs often cite insufficient educational resources and ambiguous clinical guidelines as barriers. This gap presents an opportunity for integrating targeted educational programs within primary care training frameworks to enhance preparedness for survivorship challenges.

Notably, the research team identifies several promising educational interventions designed to equip primary care clinicians with the necessary knowledge and skills. These include modular online courses, interactive workshops, webinars, and tele-mentoring programs like the Extension for Community Healthcare Outcomes (ECHO) model. The ECHO program, in particular, facilitates remote collaboration and case-based learning between oncology specialists and primary care teams, promoting shared expertise and improved patient outcomes.

The study also underscores the preference among many cancer survivors for shared-care models, where primary care and oncology specialists collaboratively engage in ongoing management. Shared-care approaches capitalize on the strengths of both disciplines: oncologists bring in-depth knowledge of cancer-specific risks and therapies, while PCCs offer longitudinal oversight of overall health, comorbidities, and preventive care. Such models can foster patient-centered continuity and potentially mitigate fragmentation.

Looking forward, the researchers aim to expand investigations into the evolving needs and preferences of cancer survivors during the survivorship phase. Understanding nuanced patient priorities—ranging from symptom management and psychosocial support to communication preferences—will be critical in designing survivorship care pathways that are not only clinically effective but also aligned with patients’ lived experiences and expectations.

This body of work contributes valuable insights into the structural and educational reforms necessary to optimize cancer survivorship care. As the survivor population grows, health systems must innovate integrated care models that adequately support primary care clinicians, promote seamless specialty-primary care coordination, and address the holistic needs of survivors.

The broader implications of these findings highlight a pressing need for policy initiatives and resource allocation to enhance survivorship training and care infrastructure. Investing in scalable educational platforms and fostering multidisciplinary collaboration will be key to meeting the anticipated demand for comprehensive survivorship services.

In sum, while advances in oncology have significantly improved survival, the continuum of care beyond treatment remains riddled with challenges. Empowering primary care providers through targeted education and structured collaborative models offers a promising avenue to bridge existing gaps. This approach is poised to redefine survivorship care and improve outcomes for millions who navigate life after cancer treatment.

The observational study titled “Continuity of Cancer Care: Female Participants’ Report of Healthcare Experiences After Conclusion of Primary Treatment” was published in the July 2025 issue of Current Oncology. Authored by experts including Jane McElroy, PhD, of the University of Missouri’s Department of Family and Community Medicine, and Mirna Becevic, PhD, from the Department of Dermatology, the study highlights essential directions for future cancer survivorship research and clinical practice.

Subject of Research: People

Article Title: Continuity of Cancer Care: Female Participants’ Report of Healthcare Experiences After Conclusion of Primary Treatment

News Publication Date: 11-Jul-2025

Web References:
DOI: 10.3390/curroncol32070399

Keywords:
Family medicine, Oncology, Cancer patients, Cancer screening, Preventive medicine, Cancer treatments